We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

22 Nov 2019 17:09

RNS Number : 4347U
Mereo BioPharma Group plc
22 November 2019
 

Mereo BioPharma Group plc

 

 ("Mereo" or the "Company")

 

Notification of Director and PDMR Dealings

London, November 22, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on November 22, 2019, Anders Ekblom, non-executive Director of Mereo, purchased 10000 American Depositary Shares (ADS) at a price of USD2.54 per ADS.

On October 04, 2019, Alastair Mackinnon, Chief Medical Officer of Mereo, purchased 15169 Ordinary Shares at a price of GBP0.59 per share. On the same day, Alastair also purchased 365 American Depositary Shares (ADS) at a price of USD3.29 per ADS.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

 

1

Details of the person discharging managerial responsibilities

a)

Name

Anders Ekblom

2

Reason for the notification

a)

Position/status

non-executive Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARES (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD2.54

10000

 

 

d)

Aggregated information: volume, Price

Aggregated volume: 10000

Aggregated price: USD2.54

e)

Date of the transaction

2019-11-22

f)

Place of the transaction

XNMS

 

 

1

Details of the person discharging managerial responsibilities

a)

Name

Alastair Mackinnon

2

Reason for the notification

a)

Position/status

Chief Medical Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC ORDINARY SHARES

 

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

GBP0.59

15169

 

 

d)

Aggregated information: volume, Price

Aggregated volume: 15169

Aggregated price: GBP0.592

e)

Date of the transaction

2019-10-04

f)

Place of the transaction

AIMX

 

 

1

Details of the person discharging managerial responsibilities

a)

Name

Alastair Mackinnon

2

Reason for the notification

a)

Position/status

Chief Medical Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD3.29

365

 

 

d)

Aggregated information: volume, Price

Aggregated volume: 365

Aggregated price: USD3.29

e)

Date of the transaction

2019-10-04

f)

Place of the transaction

XNMS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDLLFLKFFBFBV
Date   Source Headline
4th May 20177:00 amRNSInitiation of BPS-804 Phase 2b study
28th Apr 20173:37 pmRNSHolding(s) in Company
28th Apr 201712:53 pmRNSHolding(s) in Company
28th Apr 201710:05 amRNSHolding(s) in Company
26th Apr 20177:00 amRNSConversion of loan note and issue of equity
24th Apr 20176:07 pmRNSHolding(s) in Company
5th Apr 20177:00 amRNSGrant of Options and Awards
3rd Apr 20177:00 amRNSResults of Placing
31st Mar 20175:54 pmRNSResults of Placing
29th Mar 201712:30 pmRNSProposed Placing
15th Mar 20177:00 amRNSPosting of Annual Report and Notice of AGM
7th Mar 20177:00 amRNSPositive recommendation for BGS-649 Phase 2b trial
27th Feb 20177:00 amRNSPreliminary Results
20th Feb 20177:00 amRNSEMA Adaptive Pathways programme accepts BPS-804
23rd Jan 20177:05 amRNSPresentation at Shares Spotlight Evening
23rd Jan 20177:00 amRNSThree abstracts accepted for ATS Meeting
12th Jan 20177:01 amRNSDirectorate update
5th Jan 201712:00 pmRNSMereo BioPharma to Present at Biotech Showcase
12th Dec 20167:00 amRNSBusiness Update
7th Nov 20167:10 amRNSAppointment of Chief Financial Officer
3rd Nov 20167:00 amRNSPositive Phase 1 interaction study with BCT-197
5th Oct 20167:00 amRNSDirectorate Change
16th Sep 20167:00 amRNSHalf-year Report
9th Aug 20164:04 pmRNSNotice of Results
18th Jul 20161:25 pmRNSResult of AGM
30th Jun 20167:00 amRNSBPS-804 granted EU orphan drug status
24th Jun 201612:47 pmRNSNotice of AGM
9th Jun 20161:17 pmRNSDirector/PDMR Shareholding
9th Jun 20168:01 amRNSFirst Day of Dealings on AIM
10th Nov 20086:21 pmRNSFurther re financial position
4th Nov 20083:01 pmRNSStatement re suspension
4th Nov 20083:00 pmRNSSuspension
23rd Oct 20084:35 pmRNSHolding(s) in Company
23rd Oct 20082:25 pmRNSAGM Statement
2nd Oct 20083:14 pmRNSHolding(s) in Company
23rd Sep 200810:02 amRNSNotice of AGM
1st Sep 200810:06 amRNSHolding(s) in Company
29th Aug 20083:20 pmRNSResult of GM and Interim Mana
26th Aug 200810:13 amRNSHolding(s) in Company
19th Aug 20082:22 pmRNSHolding(s) in Company
14th Aug 20084:23 pmRNSHolding(s) in Company
13th Aug 200811:00 amRNSDirectorate Change
8th Aug 200811:14 amRNSHolding(s) in Company
8th Aug 200811:03 amRNSHolding(s) in Company
7th Aug 20084:46 pmRNSHolding(s) in Company
6th Aug 20084:41 pmRNSSecond Price Monitoring Extn
6th Aug 20084:36 pmRNSPrice Monitoring Extension
6th Aug 20083:17 pmRNSDirector/PDMR Shareholding
6th Aug 20087:08 amRNSFundraising and New Board App
6th Aug 20087:05 amRNSNew Joint Venture

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.